Highlight
• In an individual participant-level meta-analysis of 23,340 participants from four large randomized trials (EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, EMPA-KIDNEY), empagliflozin reduced acute kidney injury markers and adverse events, slowed chronic eGFR decline, and lowered progression to kidney failure.
• These kidney benefits were consistent across subgroups defined by predicted size of the early eGFR dip, diabetes status, heart failure status, baseline kidney function, albuminuria level, and primary kidney disease.
